Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03281577|
Recruitment Status : Completed
First Posted : September 13, 2017
Results First Posted : July 15, 2020
Last Update Posted : January 7, 2021
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Gastroparesis Idiopathic Gastroparesis||Drug: TAK-954 Drug: Placebo||Phase 2|
The drug being tested in this study is called TAK-954. TAK-954 is a serotonin (5 HT4) receptor agonist and is being tested to treat people who have diabetic or idiopathic gastroparesis and who previously reported delay in stomach emptying. This study will look at the gastric emptying time of solids in people who take TAK-954 or placebo.
The study will enroll approximately 41 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
- TAK-954 0.1 mg
- TAK-954 0.3 mg
- TAK-954 1 mg
- Placebo (dummy inactive solution) - this is a solution that looks like the study drug but has no active ingredient.
This single center trial will be conducted in the United States. The duration of treatment is 3 days and the overall period of evaluation is up to 28 days. The participants will be contacted by telephone (Days 10 to 14) for follow-up assessment. There will be another follow-up phone call for women of childbearing potential (Days 38 to 43).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis|
|Actual Study Start Date :||January 2, 2018|
|Actual Primary Completion Date :||June 7, 2019|
|Actual Study Completion Date :||July 12, 2019|
Placebo Comparator: Placebo
TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once daily on Days 1 to 3.
TAK-954 placebo-matching IV infusion.
Experimental: TAK-954 0.1 mg
TAK-954 0.1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
TAK-954 IV infusion.
Experimental: TAK-954 0.3 mg
TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
TAK-954 IV infusion.
Experimental: TAK-954 1 mg
TAK-954 1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
TAK-954 IV infusion.
- Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids [ Time Frame: Predose and at multiple time-points post-dose (up to 9 hours) on Day 2 ]Half-emptying time (t1/2) of gastric solids is the time for half of the ingested solids or liquids to leave the stomach. Scintigraphy assessments were used to evaluate the gastric emptying of solids following a radio-labelled meal. A negative percent change from baseline indicated improvement.
- Colonic Geometric Center [ Time Frame: 4, 24, and 48 hours post-radiolabeled meal on Day 2 ]The scintigraphic method was used to measure colonic geometric center following a radio-labelled meal. The geometric center (GC) was the weighted average of counts in the different colonic regions, where 0= no radioactivity in the colon and if radioactivity was detected in the colon, 1=all isotope was in the ascending colon and 5=all isotope was in the stool; a high GC indicated faster colonic transit.
- Colonic Filling at Hour 6 [ Time Frame: 6 hours post-radiolabel meal on Day 2 ]Colonic filling was estimated as percentage of the radio-labelled meal that reached the colon at Hour 6.
- Half-emptying Time (T1/2) of Ascending Colon [ Time Frame: Predose and at multiple time-points post-dose (up to 25 hours) on Days 1, 2 and 3 ]T1/2 of ascending colon emptying was estimated by analysis of proportionate emptying over time of counts from the colon. Scintigraphy assessments were used to evaluate the emptying of solids or liquids from ascending colon following a radio-labelled meal.
- AUCtau: Area Under the Plasma Concentration-Time Curve From Time 0 to t for TAK-954 [ Time Frame: Predose and at multiple time-points post-dose (up to 25 hours) on Days 1, 2 and 3 ]
- Cmax: Maximum Observed Plasma Concentration for TAK-954 [ Time Frame: Predose and at multiple time-points post-dose (up to 25 hours) on Days 1, 2 and 3 ]
- Ctrough: Observed Plasma Concentration at the End of a Dosing Interval [ Time Frame: At multiple time-points post-dose, up to 9 hours on Day 2 and up to 25 hours on Day 3 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Has diabetes mellitus with symptoms of gastroparesis and previously documented gastric emptying delay or previously documented idiopathic gastroparesis in the last 5 years.
- Has a body mass index (BMI) greater than or equal to (>=) 16 and less than or equal to (<=) 40 kilogram per square meter (kg/m^2) at the Screening Visit.
- Has glycosylated hemoglobin (HbA1c) greater than (>) 12 percent (%).
- Has other structural diseases/conditions that affect the gastrointestinal (GI) system.
- Are unable to withdraw drugs known to alter GI transit 48 hours prior to the study.
- Has clinically significant abnormal baseline safety laboratory values.
- Has preexisting hepatic disease that meets Child-Pugh Class B (moderate; total score 7 to 9 points) or C (severe; total score 10 to 15 points).
Are without known preexisting hepatic disease who have 1 or more of the following:
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 times the upper limit of normal (ULN).
- Bilirubin >1.5 times the ULN unless due to Gilbert's syndrome.
- International normalized ratio (INR) >1.5 unless on anticoagulation therapy.
- Has QT intervals with Fridericia correction method (QTcF) interval (>=) 460 millisecond (msec) or with other factors that increase the risk of QT prolongation or arrhythmic events at screening. Note: Participants with bundle branch block and a prolonged QTc interval, or with QTcF between 450 and 460 msec, should be reviewed by the Medical Monitor for potential inclusion.
- Has second or third degree atrioventricular (AV) block; AV disassociation; >5 beats of non-sustained VT at a rate >120 beats per minute (bpm); Electrocardiogram (ECG) changes consistent with acute myocardial ischemia or infarction.
- Has cardiac history that includes conditions requiring heart rate control (example, atrial fibrillation, atrial flutter, ventricular tachycardia, or other tachyarrhythmias).
- Has clinical evidence (including physical examination, ECG, clinical laboratory value and review of the medical history) of significant cardiovascular, respiratory, moderate or severe renal insufficiency (creatinine clearance <=60 mL/min), hematological, neurological, or psychiatric disease, or other disease that interferes with the objectives of the study.
- If female, are pregnant or lactating or intending to become pregnant before participating in this study, during the study, and 4 to 5 days (5 half-lives) PLUS 30 days after last dose of the study drug; or intending to donate ova during such time period.
- Are considered by the investigator to be alcoholics not in remission or known substance abusers. Have a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to: beer [354 milliliter per [mL/] 12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce] per day).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03281577
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Study Director:||Medical Director Clinical Science||Takeda|
Documents provided by Takeda:
|Other Study ID Numbers:||
U1111-1200-9396 ( Registry Identifier: WHO )
|First Posted:||September 13, 2017 Key Record Dates|
|Results First Posted:||July 15, 2020|
|Last Update Posted:||January 7, 2021|
|Last Verified:||December 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
|Access Criteria:||IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Digestive System Diseases